The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis

Bo Shen, Darrell S. Pardi, Ana E. Bennett, Elaine Queener, Patricia Kammer, Jefferey P. Hammel, Caroline LaPlaca, M. Scott Harris

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


OBJECTIVES:Although a majority of patients with pouchitis respond favorably to antibiotic therapy, many relapse frequently, and nonabsorbable and non-antibiotic-based agents are desirable for reducing bacterial resistance and the systemic adverse effects associated with long-term antibiotic exposure. AST-120 (a spherical carbon adsorbent) comprises highly adsorptive, porous carbon microspheres with the ability to adsorb small-molecular-weight toxins, inflammatory mediators, and harmful bile acids. The aim of this pilot trial was to evaluate the efficacy and tolerability of AST-120 in the treatment of active pouchitis.METHODS:Eligible patients were recruited from two subspecialty pouchitis clinics. Inclusion criteria were (i) ileal pouch-anal anastomosis performed for ulcerative colitis; (ii) active pouchitis with Pouchitis Disease Activity Index (PDAI) scores 7; and (iii) discontinuation of antibiotic therapy for at least 2 weeks. Exclusion criteria included Crohn's disease of the pouch, isolated cuffitis, pouch strictures, abscess, and sinuses. All eligible patients received AST-120 in 2-g sachets (oral) open label, thrice a day for 4 weeks. The primary efficacy end point was remission as defined by a PDAI score of <7 points; the main secondary end point was clinical response, defined by a reduction of the PDAI score of 3 points.RESULTS:Nineteen of 20 patients completed the trial. Eleven patients (55.0) had a clinical response to the therapy and 10 patients (50.0) entered remission. Median reduction in the PDAI symptom, endoscopy, and histology subscores, and PDAI total scores after 4 weeks were -2 (P0.002), -2 (P0.003), 0 (P0.32), and -4 (P0.001) points, respectively. The agent was well tolerated; one patient experienced transient mild elevation of alkaline phosphatase of uncertain significance and one patient experienced an upper respiratory infection after taking one dose of AST-120 and was excluded from the final analysis for the calculation of pre- and post-trial PDAI scores.CONCLUSIONS:AST-120 seems to be effective and well tolerated in treating patients with active pouchitis. A randomized, placebo-controlled trial is warranted for assessing the long-term efficacy and safety of AST-120 in the disease.

Original languageEnglish (US)
Pages (from-to)1468-1478
Number of pages11
JournalAmerican Journal of Gastroenterology
Issue number6
StatePublished - Jun 1 2009

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis'. Together they form a unique fingerprint.

Cite this